VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: The Software IPO Drought Behind 2026's Infra Boom
Value Add VC/Pulse/IPOInfra IPOs vs thin software pipeline

The Software IPO Drought Behind 2026's Infra Boom

SK Hynix, Csquare, Standard Nuclear and Meta's $50B Louisiana buildout keep winning capital while pure application-layer software IPOs stay scarce -- a gap that's now wide enough to be the real 2026 IPO story.

By the Numbers

$50B+
Meta Louisiana cost
$1.8B at $18B
Helsing round
$1.25B
Csquare IPO target
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 14, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

This year's largest and best-received public and pre-IPO capital events -- SK Hynix's record Nasdaq debut, Csquare's roughly $1.25 billion data-center listing, Standard Nuclear's SMR-focused raise, Meta's $50 billion-plus Louisiana data center, Helsing's $1.8 billion defense round -- are overwhelmingly physical AI infrastructure, not application-layer software

2

Pure application-layer software IPOs have been comparatively scarce in 2026's listing calendar, even as venture funding for AI-native software companies remains substantial at the private-market stage

3

The gap suggests public-market investors are drawing a sharper line than private markets between infrastructure businesses with multi-year replication lead times and software products facing faster commoditization from rapid model releases

4

Plaid's considered IPO at an $8 billion valuation is one of the few non-infrastructure listings generating real attention this year, underscoring just how thin the software IPO pipeline currently is relative to infrastructure

TC

The VC Read · Trace's Take

Trace Cohen

The absence is the story -- I can name five infrastructure IPOs and mega-rounds from this week alone, and I'm struggling to name a single pure application-layer AI software company anywhere close to a 2026 listing. If you're building an AI-native software company with a public exit in mind, the bar right now isn't 'ship a good product,' it's 'build something a public investor believes can't be replicated by whatever model ships next month.'

Analysis

Look at the largest capital events of the past week alone -- Meta's Louisiana data center confirmed at more than $50 billion, Helsing's $1.8 billion Series E at an $18 billion valuation, Csquare's roughly $1.25 billion data-center IPO, Standard Nuclear's SMR-focused listing -- and a pattern that's been building all year becomes impossible to ignore: 2026's largest public and pre-IPO capital events are overwhelmingly going to physical AI infrastructure, not application-layer software.

What's missing is just as telling as what's present. Pure application-layer AI software companies -- products built on top of frontier models rather than the infrastructure underneath them -- have produced comparatively few major 2026 IPOs, even as private venture funding for AI-native software companies remains substantial at the growth and late stage. That's a real divergence: private markets keep funding application-layer software generously, but public markets aren't yet rewarding those companies with comparable listing enthusiasm.

The likely explanation is durability, and it's the same logic that's applied throughout this year's infrastructure-favoring IPO pattern: a fab, a data center, a power plant or a defense-AI platform with government contracts takes years to replicate regardless of how fast software iterates on top of it, while application-layer AI products face genuine commoditization risk as frontier labs ship new model tiers roughly every two weeks and open-weight alternatives compress margins across nearly every software category. Public investors, who generally demand more certainty about multi-year durability than late-stage private investors do, appear to be pricing that gap explicitly.

“Public investors, who generally demand more certainty about multi-year durability than late-stage private investors do, appear to be pricing that gap explicitly.”

Plaid's considered $8 billion IPO is one of the only non-infrastructure listings generating real attention this year, and even that's a fintech infrastructure business -- bank-account connectivity APIs -- rather than a pure AI application-layer company, underscoring just how thin the actual software IPO pipeline is relative to the infrastructure side of the market.

For software-focused VCs and founders, the gap is a genuine strategic signal: building durable competitive moats -- proprietary data, deep enterprise integration, regulatory approval, physical distribution -- matters more than ever if the goal is an eventual public listing, because pure model-wrapper software companies are facing a much harder public-market bar than infrastructure businesses right now. For infrastructure investors, the pattern is confirmation that the premium public markets are paying for physical AI infrastructure isn't a temporary quirk of this particular IPO season -- it's shaping up to be the defining structural feature of the entire 2026 listing year.

The bear case: this could simply reflect which companies happen to be ready to list this particular year rather than a durable public-market preference, and a wave of mature application-layer AI software companies reaching IPO readiness in 2027 could reverse the pattern quickly. What to watch next: whether any major AI-native application-layer software company files for a 2026 US IPO in the back half of the year, which would be the clearest test of whether this gap is structural or simply a function of company-readiness timing.

ShareXLinkedInEmail

More on

Meta →SK Hynix →Csquare →

Reported by Value Add Pulse Analysis · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

Latigo Biotherapeutics Jumps 17% in $345.6M IPO

Illustration for: Latigo Biotherapeutics Jumps 17% in $345.6M IPO
IPO$345.6M IPO

Latigo Biotherapeutics Jumps 17% in $345.6M IPO

Latigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 9, 2026

Caris Leads a Wild Week for Recent IPO Stocks

Illustration for: Caris Leads a Wild Week for Recent IPO Stocks
IPO

Caris Leads a Wild Week for Recent IPO Stocks

Caris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.

@Trace_Cohen·t@nyvp.com